HIGHLIGHTS
- who: Natalie Arnold from the Department of Cardiology, University Heart and Vascular Center Hamburg, Hamburg, Germany have published the research work: PCSK9 Inhibitor Wars: How Does Inclisiran Fit in with Current Monoclonal Antibody Inhibitor Therapy? Considerations for Patient Selection, in the Journal: (JOURNAL)
- what: In this narrative review, the authors focus on current strategies targeting PCSK9 and critically discuss some uncertainties regarding the allocation strategy, paying particular attention on the role of inclisiran in the treatment of dyslipidemia in high-/very high-risk subjects.
- future: More research in larger patient populations is urgently . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.